SY0916

platelet-activating factor receptor antagonist; structure in first source

Networked: 3 relevant articles (0 outcomes, 2 trials/studies)

1.	Pulmonary Fibrosis (Fibrosing Alveolitis) 01/01/2014 - "These findings demonstrated that SY0916 could possibly be developed as a promising candidate for the treatment of pulmonary fibrosis. " 01/01/2014 - "The inhibition effect and mechanism of SY0916 on pulmonary fibrosis." 01/01/2014 - "In this study, the inhibitory effect of SY0916 on pulmonary fibrosis was investigated in epithelial-mesenchymal transition (EMT) induced by transforming growth factor beta 1 (TGF-β1) in vitro and a pulmonary fibrosis animal model induced by bleomycin (BLM). " 01/01/2014 - "In vivo, SY0916 administration significantly ameliorated the BLM-mediated histological changes, reduced main biochemical parameters related to pulmonary fibrosis such as hydroxyproline and glutathione, and also notably attenuated the expression of key pro-fibrotic mediator, TGF-β1. "
2.	Rheumatoid Arthritis 01/01/2019 - "SY0916 has been proven to be a potent treatment agent against rheumatoid arthritis in preclinical studies and has been shown to be safe in phase I clinical trials. "
3.	Bone Resorption 04/01/2010 - "SY0916 significantly inhibited the proliferation of OCLs, decreased both the total and average area of bone resorption pits, and dramatically inhibited the number of osteoclasts between concentrations of 0.01 and 10 micromol/L. "

1.	Transforming Growth Factor beta (TGF-beta)
2.	Bleomycin (Blenoxane)
3.	Hydroxyproline (4 Hydroxyproline)
4.	Glutathione (Reduced Glutathione)